ClinicalTrials.gov
public full text
Public Domain
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
breast-cancercholangiocarcinomacolorectal-canceresophageal-cancergastric-cancermelanomanon-small-cell-lung-cancerovarian-cancer
This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy in expansion cohorts once the MTD is determined.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study of the CD40 Agonistic Monoclonal Antibody APX005M#1060495
- CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations#877725
- CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors#847862
- A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma#1071832
- Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies#810799
Record · ID 901932
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive